The clinical site, located in Texas, will serve as the first participating center in Polyrizon's planned multi-center study evaluating the safety, tolerability, and efficacy of the NASARIXTM Allergy Blocker in patients with seasonal allergic rhinitis.

The clinical study, titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis", will assess the performance of Polyrizon's investigational nasal spray designed to create a protective barrier against airborne allergens.

"This agreement represents an important step in transitioning NASARIXTM from development stage into potential clinical validation," said Tomer Izraeli, CEO of Polyrizon. "We are pleased to collaborate with an experienced clinical team as we advance toward initiating our first-in-human clinical study."

The study is planned as a multi-center trial, with additional clinical sites expected to be added in the coming months. The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting Polyrizon's broader regulatory strategy.

NASARIXTM is an investigational intranasal formulation designed to provide a non-pharmacological barrier against allergens, with the goal of preventing allergic reactions at the point of entry.